Adagene to Participate in the Guggenheim Securities 3rd Annual Healthcare Innovation Conference
Globe Newswire•27/10/2026•07:00 ET
0
Key Highlights
- ➤Adagene (ADAG) management to join Guggenheim healthcare conference fireside chat November 9
- ➤Adagene management will hold one-on-one investor meetings during the November 9-11 conference
- ➤Muzastotug (ADG126) is being evaluated in Phase 1b/2 and Phase 2 studies
- ➤FDA granted Fast Track designation to muzastotug plus pembrolizumab in MSS metastatic CRC
SAN DIEGO and SUZHOU, China, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today announced that senior management will participate in a fireside chat and one-on-one meetings at the Guggenheim Securities 3rd Annual Healthcare Innovation Conference being held November 9-11, 2026 in Boston, MA.
Guggenheim Securities 3rd Annual Healthcare Innovation Conference Format: Fireside Chat and 1x1 Meetings Date: November 9, 2026 Time: 9:00 – 9:25 a.m. ET
Get started
Create a free account to read the full story.